Meta-Analysis Comparing Potent Oral P2Y 12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
ConclusionsIn patients receiving OAC therapy for AF after a recent PCI, potent oral P2Y12 inhibitors increase the risk of clinically relevant bleeding compared with clopidogrel, with no evident benefit in terms of MACE reduction.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Angioplasty | Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Databases & Libraries | Heart | Percutaneous Coronary Intervention | Plavix